phrykt

Spyre Therapeutics, Inc. (SYRE): who owns it and who trades it

As of Nov 16, 2026, SYRE insiders reported 94 open-market sales worth $442M and no purchases in the last 12 months, with 9% of the sale value made under pre-set 10b5-1 plans. The largest seller was Fairmount Funds Management LLC (Director), with $400M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Spyre Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SYRE

263 funds and institutions reported SYRE shares worth $8.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
BlackRock, Inc.7.5%
Perceptive Advisors LLC5.0%
Rtw Investments, LP4.9%
Paradigm Biocapital Advisors LP4.4%
Vanguard Capital Management LLC4.0%
State Street Corp3.5%
Venrock Adviser, LLC3.4%
T. Rowe Price Associates3.4%
Driehaus Capital Management LLC3.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)13.03M15.00%$1.2B+11%
BlackRock, Inc.6.51M7.49%$578M+18%
Perceptive Advisors LLC4.32M4.97%$383M+14%
Rtw Investments, LP4.25M4.90%$377M+2%
Paradigm Biocapital Advisors LP3.84M4.42%$341M+96%
Vanguard Capital Management LLC3.45M3.97%$306M+13%
State Street Corp3.06M3.52%$271M+17%
Venrock Adviser, LLC2.99M3.44%$265M-19%
T. Rowe Price Associates2.96M3.41%$263M+85%
Driehaus Capital Management LLC2.80M3.22%$249M+0%
Geode Capital Management, LLC2.56M2.95%$239M+49%
Vanguard Portfolio Management LLC2.33M2.68%$207M+298%
Capital World Investors2.32M2.67%$206M+247%
Jupiter Topco LLC2.21M2.54%$196M–
TCG Crossover Management, LLC1.90M2.19%$169MNo change
Tang Capital Management LLC1.89M2.18%$168MNo change
Bank of America Corp1.78M2.05%$158M+45%
Adage Capital Partners Gp, L.l.c.1.72M1.98%$153M–
Wellington Management Group LLP1.58M1.82%$140M-13%
Goldman Sachs Group Inc1.48M1.70%$131M+448%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SYRE insiders reported $0 of open-market purchases and $442M of sales. 9% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$442M
94 trades, 7 people
Sales under a 10b5-1 plan
9%
Share of sale value
Latest trade
Oct 1, 2026
Filed Oct 2, 2026

Purchases and sales by month

$405M$405MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 1, 2026Scott L BurrowsCFOSale plan600$89.07$53.4KForm 4
Oct 1, 2026Scott L BurrowsCFOSale plan1,500$90.27$135KForm 4
Oct 1, 2026Scott L BurrowsCFOSale plan2,100$91.92$193KForm 4
Oct 1, 2026Scott L BurrowsCFOSale plan3,071$92.95$285KForm 4
Oct 1, 2026Scott L BurrowsCFOSale plan229$93.57$21.4KForm 4
Oct 1, 2026Heidy King-JonesSee RemarksSale plan400$89.24$35.7KForm 4
Oct 1, 2026Heidy King-JonesSee RemarksSale plan16,605$90.35$1.5MForm 4
Oct 1, 2026Heidy King-JonesSee RemarksSale plan7,228$91.35$660KForm 4
Oct 1, 2026Heidy King-JonesSee RemarksSale plan2,100$92.70$195KForm 4
Oct 1, 2026Heidy King-JonesSee RemarksSale plan2,600$93.46$243KForm 4
Oct 1, 2026Cameron TurtleCEOSale plan600$89.14$53.5KForm 4
Oct 1, 2026Cameron TurtleCEOSale plan2,683$90.10$242KForm 4
Oct 1, 2026Cameron TurtleCEOSale plan2,638$91.49$241KForm 4
Oct 1, 2026Cameron TurtleCEOSale plan3,989$92.31$368KForm 4
Oct 1, 2026Cameron TurtleCEOSale plan4,990$93.37$466KForm 4
Oct 1, 2026Cameron TurtleCEOSale plan100$93.91$9.4KForm 4
Sep 30, 2026Scott L BurrowsCFOSale plan17,500$89.89$1.6MForm 4
Sep 2, 2026Heidy King-JonesSee RemarksSale plan400$90.00$36KForm 4
Sep 2, 2026Scott L BurrowsCFOSale plan18,232$89.35$1.6MForm 4
Sep 1, 2026Heidy King-JonesSee RemarksSale plan4,845$86.40$419KForm 4
Sep 1, 2026Heidy King-JonesSee RemarksSale plan16,548$87.20$1.4MForm 4
Sep 1, 2026Heidy King-JonesSee RemarksSale plan6,206$88.17$547KForm 4
Sep 1, 2026Heidy King-JonesSee RemarksSale plan400$89.38$35.8KForm 4
Sep 1, 2026Scott L BurrowsCFOSale plan200$89.04$17.8KForm 4
Sep 1, 2026Scott L BurrowsCFOSale plan2,016$88.03$177KForm 4
Sep 1, 2026Scott L BurrowsCFOSale plan900$86.25$77.6KForm 4
Sep 1, 2026Scott L BurrowsCFOSale plan4,384$87.11$382KForm 4
Sep 1, 2026Cameron TurtleCEOSale plan8,400$87.15$732KForm 4
Sep 1, 2026Cameron TurtleCEOSale plan2,500$86.36$216KForm 4
Sep 1, 2026Cameron TurtleCEOSale plan400$89.07$35.6KForm 4
Sep 1, 2026Cameron TurtleCEOSale plan3,700$88.06$326KForm 4
Aug 7, 2026Jeffrey W. AlbersDirectorSale plan5,000$104.47$522KForm 4
Aug 7, 2026Jeffrey W. AlbersDirectorSale plan8,000$104.38$835KForm 4
Aug 7, 2026Jeffrey W. AlbersDirectorSale plan10,000$104.68$1MForm 4
Aug 3, 2026Scott L BurrowsCFOSale plan2,300$96.30$221KForm 4
Aug 3, 2026Scott L BurrowsCFOSale plan5,100$95.21$486KForm 4
Aug 3, 2026Scott L BurrowsCFOSale plan100$97.10$9.7KForm 4
Aug 3, 2026Cameron TurtleCEOSale plan800$93.97$75.2KForm 4
Aug 3, 2026Cameron TurtleCEOSale plan7,157$95.10$681KForm 4
Aug 3, 2026Cameron TurtleCEOSale plan5,635$95.93$541KForm 4
Aug 3, 2026Cameron TurtleCEOSale plan1,392$96.82$135KForm 4
Aug 3, 2026Cameron TurtleCEOSale plan16$97.46$1.6KForm 4
Jul 1, 2026Scott L BurrowsCFOSale plan5,775$87.55$506KForm 4
Jul 1, 2026Scott L BurrowsCFOSale plan1,725$88.37$152KForm 4
Jul 1, 2026Sheldon SloanChief Medical OfficerSale plan1,834$88.34$162KForm 4
Jul 1, 2026Sheldon SloanChief Medical OfficerSale plan6,500$87.52$569KForm 4
Jul 1, 2026Cameron TurtleCEOSale plan4,234$88.12$373KForm 4
Jul 1, 2026Cameron TurtleCEOSale plan590$88.91$52.5KForm 4
Jul 1, 2026Cameron TurtleCEOSale plan10,176$87.44$890KForm 4
Jun 25, 2026Scott L BurrowsCFOSale5,000$87.12$436KForm 4
Jun 25, 2026Scott L BurrowsCFOSale10,000$87.14$871KForm 4
Jun 23, 2026Fairmount Funds Management LLC +3DirectorSale4.68M$85.31$400MForm 4
Jun 22, 2026Michael Thomas HendersonDirectorSale plan20,000$100.00$2MForm 4
Jun 3, 2026Sheldon SloanChief Medical OfficerSale plan8,333$75.00$625KForm 4
Jun 1, 2026Cameron TurtleCEOSale plan3,294$71.38$235KForm 4
Jun 1, 2026Cameron TurtleCEOSale plan8,149$70.50$575KForm 4
Jun 1, 2026Cameron TurtleCEOSale plan3,557$69.40$247KForm 4
Jun 1, 2026Scott L BurrowsCFOSale plan3,100$72.06$223KForm 4
Jun 1, 2026Scott L BurrowsCFOSale plan2,599$70.77$184KForm 4
Jun 1, 2026Scott L BurrowsCFOSale plan1,801$69.75$126KForm 4
May 8, 2026Michael Thomas HendersonDirectorSale plan2,404$72.57$174KForm 4
May 8, 2026Michael Thomas HendersonDirectorSale plan24,814$74.76$1.9MForm 4
May 8, 2026Michael Thomas HendersonDirectorSale plan19,269$75.35$1.5MForm 4
May 8, 2026Michael Thomas HendersonDirectorSale plan33,513$73.72$2.5MForm 4
May 1, 2026Scott L BurrowsCFOSale plan12,500$71.37$892KForm 4
May 1, 2026Sheldon SloanChief Medical OfficerSale plan5,059$74.60$377KForm 4
May 1, 2026Sheldon SloanChief Medical OfficerSale plan10,358$73.74$764KForm 4
May 1, 2026Sheldon SloanChief Medical OfficerSale plan12,777$72.94$932KForm 4
May 1, 2026Sheldon SloanChief Medical OfficerSale plan8,777$71.56$628KForm 4
May 1, 2026Sheldon SloanChief Medical OfficerSale plan19,656$70.61$1.4MForm 4
May 1, 2026Sheldon SloanChief Medical OfficerSale plan400$75.37$30.1KForm 4
May 1, 2026Sheldon SloanChief Medical OfficerSale plan21,306$69.53$1.5MForm 4
May 1, 2026Cameron TurtleCEOSale plan3,100$73.14$227KForm 4
May 1, 2026Cameron TurtleCEOSale plan1,000$71.76$71.8KForm 4
May 1, 2026Cameron TurtleCEOSale plan3,600$70.77$255KForm 4
May 1, 2026Cameron TurtleCEOSale plan5,300$69.54$369KForm 4
May 1, 2026Cameron TurtleCEOSale plan300$74.96$22.5KForm 4
May 1, 2026Cameron TurtleCEOSale plan1,700$74.23$126KForm 4
Apr 1, 2026Cameron TurtleCEOSale plan2,656$49.92$133KForm 4
Apr 1, 2026Cameron TurtleCEOSale plan12,344$49.20$607KForm 4
Apr 1, 2026Sheldon SloanChief Medical OfficerSale plan7,958$50.00$398KForm 4
Apr 1, 2026Scott L BurrowsCFOSale plan6,200$49.21$305KForm 4
Apr 1, 2026Scott L BurrowsCFOSale plan1,300$49.98$65KForm 4
Mar 3, 2026Scott L BurrowsCFOSale plan200$41.66$8.3KForm 4
Mar 3, 2026Scott L BurrowsCFOSale plan2,300$40.56$93.3KForm 4
Mar 2, 2026Cameron TurtleCEOSale plan9,100$42.49$387KForm 4
Mar 2, 2026Cameron TurtleCEOSale plan5,900$41.73$246KForm 4
Feb 2, 2026Cameron TurtleCEOSale plan957$31.82$30.5KForm 4
Feb 2, 2026Cameron TurtleCEOSale plan14,043$32.87$462KForm 4
Jan 2, 2026Cameron TurtleCEOSale plan12,709$30.47$387KForm 4
Jan 2, 2026Cameron TurtleCEOSale plan100$32.39$3.2KForm 4
Jan 2, 2026Cameron TurtleCEOSale plan2,191$31.79$69.7KForm 4
Dec 1, 2025Cameron TurtleCEOSale plan4,005$29.83$119KForm 4
Dec 1, 2025Cameron TurtleCEOSale plan10,995$28.73$316KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Fairmount Funds Management LLCDirector–$400MJun 23, 2026
Cameron TurtleChief Executive Officer, Director–$10.3MOct 1, 2026
Scott L BurrowsChief Financial Officer–$9.1MOct 1, 2026
Michael Thomas HendersonDirector–$8MJun 22, 2026
Sheldon SloanChief Medical Officer–$7.4MJul 1, 2026
Heidy King-JonesSee Remarks–$5.1MOct 1, 2026
Jeffrey W. AlbersDirector–$2.4MAug 7, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SYRE short interest

High short interest. 12.2% of SYRE shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 6%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.62M SYRE shares were sold short, 12.2% of the shares outstanding, down 7.1% from the report before. At the average daily volume of 915,434 shares, buying them all back would take about 12.7 trading days (days to cover).

Shares short, % of all shares

12.2%May 15Oct 3016.2%

Days to cover

12.7May 15Oct 3017.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.62M12.23%-7%915,43412.7
Oct 15, 202612.51M14.18%-3%1.70M7.3
Sep 30, 202612.84M14.57%+6%1.44M8.9
Sep 15, 202612.13M13.76%+2%1.05M11.6
Aug 31, 202611.86M13.45%+1%1.22M9.7
Aug 14, 202611.76M13.33%-3%736,81715.9
Jul 31, 202612.14M13.77%-3%898,54713.5
Jul 15, 202612.51M14.40%-8%1.39M9.0
Jun 30, 202613.64M15.71%+8%2.46M5.6
Jun 15, 202612.62M14.53%-0%1.17M10.8
May 29, 202612.63M14.54%+2%816,17815.5
May 15, 202612.42M14.30%+2%1.19M10.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Spyre Therapeutics company events

Spyre Therapeutics filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Oct 7, 2026AgreementSpyre Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as the representatives of the underwriters named therein, relating to the offer and sale of 4,117,648 shares of the… Filing
  3. Sep 8, 2026AnnouncementThe Company announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely active UC. SPY003 SKYLINE Part A Induction Topline Results Efficacy: POC Established Across All Three… Filing
  4. Aug 25, 2026AnnouncementThe Company announced topline results from the RA sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Filing
  5. Aug 4, 2026ResultsReleased financial results. Filing
  6. Jun 15, 2026AnnouncementThe Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 for the treatment of moderately-to-severely active UC. SPY002 SKYLINE Part A Induction Topline Results Initial 12-week findings from SKYLINE Part A demonstrated that SPY002 met… Filing
  7. Jun 1, 2026AnnouncementThe Company entered into the First Amendment to Amended and Restated License Agreement, amending the Amended and Restated License Agreement dated as of February 24, 2025 (as amended, the "SPY003 License Agreement"), by and between the Company and Paragon Therapeutics, Inc. Filing
  8. May 29, 2026LeadershipAs discussed in Item 5.07 below, upon the recommendation of the Board of Directors of Spyre Therapeutics, Inc., the stockholders of the Company, at the Company’s Annual Meeting of Stockholders held on May 27, 2026, approved the amended and restated 2016 Employee Stock Purchase Plan. Filing
  9. May 5, 2026ResultsReleased financial results. Filing
  10. Apr 16, 2026AgreementSpyre Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein, relating to the offer and sale of 6,500,000 shares of the Company’s common… Filing
  11. Apr 13, 2026AnnouncementThe Company suspended and terminated the prospectus relating to the sale of its common stock, $0.0001 par value per share in an “at-the-market” offering pursuant to the terms of the Sales Agreement, dated, September 6, 2024, by and between the Company and TD Securities (USA) LLC. Filing
  12. Apr 13, 2026AnnouncementThe Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC. Additionally, the Company announced that recruitment for Part A of the SKYLINE Trial is now closed and enrollment is open for… Filing
  13. Feb 19, 2026ResultsReleased financial results. Filing
  14. Jan 12, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Spyre Therapeutics financials

Famous investors that hold SYRE

3 of the 50 well-known investors we track reported holding SYRE in their latest 13F filing. The largest position is Steve Cohen's, worth $31.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026356,923$31.8M0.1%New
Israel Englander · Millennium ManagementQ3 2026241,548$21.5M0.0%+23%
Ken Griffin · Citadel AdvisorsQ3 202620,097$1.8M0.0%-81%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SYRE in the last 120 days.

FiledHolderFormStake
Oct 9, 2026Fairmount Funds Management LLC13D/A9.2%
Oct 9, 2026Fairmount Funds Management LLC13D/A9.2%
Oct 1, 2026Paradigm BioCapital Advisors LP13G5.1%
Oct 1, 2026Paradigm BioCapital Advisors LP13G5.1%

Questions about Spyre Therapeutics, Inc. (SYRE) stock

Who owns the most SYRE stock?

The largest reported owner of Spyre Therapeutics, Inc. (SYRE) is FMR LLC (Fidelity), with 15.0% of the company. In total, 263 funds and institutions reported holding SYRE at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are SYRE insiders buying or selling?

In the last 12 months, SYRE insiders reported no open-market purchases and 94 sales worth $442M. The latest trade was on Oct 1, 2026. See every trade.

What is the short interest in SYRE?

As of Oct 30, 2026, 11.62M SYRE shares were sold short, 12.2% of the shares outstanding, down 7.1% from the report before. At the average daily volume of 915,434 shares, buying them all back would take about 12.7 trading days (days to cover). See the history.

Which famous investors hold SYRE?

3 of the 50 well-known investors we track reported SYRE in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $31.8M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.